KERX Financial Facts

Loss before income taxes: -35.29M
Total research and development: 19.05M
See Full Income Statement

Other assets, net: 292K
Short-term investment securities: 34.1M
See Full Balance Sheet

Keryx Biopharmaceuticals Inc. (KERX) Earnings

  |   Expand Research on KERX
Next EPS Date 3/12/15 *Est. EPS Growth Rate -100.0% *Last Qtr.
Average EPS % Beat Rate -38.9% Revenue Growth Rate N/A
Average % Move 1-Wk after EPS +0.5% Normal Earnings Time Before Open
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
11/6/14 Q314 -$0.38-$0.27 -$0.11$256K$150K N/A Details
8/7/14 Q214 -$0.24-$0.25 +$0.01N/AN/A N/A Details
5/8/14 Q114 -$0.15-$0.08 -$0.07$10M$9.91M N/A Details
3/12/14 Q413 -$0.21-$0.16 -$0.05N/A$2.22M N/A Details
11/4/13 Q313 -$0.19-$0.11 -$0.08N/A$2.22M N/A Details
7/31/13 Q213 -$0.14-$0.10 -$0.04N/AN/A N/A Details
5/7/13 Q113 -$0.03-$0.01 -$0.02$7M$5.83M N/A Details
3/11/13 Q412 -$0.09-$0.08 -$0.01N/AN/A N/A Details